Long-term protective efficacy of the Escherichia coli- produced HPV-16/18 bivalent human papillomavirus vaccine in women vaccinated at 18-45 years: A 9-year follow-up study
{{output}}
Background: To assess the enduring protective efficacy of the recombinant human papilloma virus (HPV) 16/18 bivalent vaccine (produced in Escherichia coli) in preventing HPV infection. ... ...
